عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

King Abdulaziz Royal Reserve Contributes to Saudi Green Initiative’s Goals

CEO of the King Abdulaziz Royal Reserve Development Authority Eng. Maher bin Abdullah Al-Gothmi. (SPA)
CEO of the King Abdulaziz Royal Reserve Development Authority Eng. Maher bin Abdullah Al-Gothmi. (SPA)
TT
TT

King Abdulaziz Royal Reserve Contributes to Saudi Green Initiative’s Goals

CEO of the King Abdulaziz Royal Reserve Development Authority Eng. Maher bin Abdullah Al-Gothmi. (SPA)
CEO of the King Abdulaziz Royal Reserve Development Authority Eng. Maher bin Abdullah Al-Gothmi. (SPA)

The CEO of the King Abdulaziz Royal Reserve Development Authority, Eng. Maher bin Abdullah Al-Gothmi, described Saudi Green Initiative Day as a celebration of Saudi Arabia's achievements in the field of climate action and addressing various environmental challenges.
Al-Gothmi added that the event, which falls on March 27, is an opportunity to unify the efforts of Saudi society members and activate their role in building a sustainable future, the Saudi Press Agency said on Thursday.
"Thank God and under the guidance and follow-up of Prince Abdulaziz bin Saud bin Naif, the chairman of the board of directors of the King Abdulaziz Royal Reserve Development Authority, has succeeded in aligning its projects, initiatives, and outputs with the targets of the Saudi Green Initiative since its launch by His Royal Highness the Crown Prince on March 27, 2021”, said Al-Gothmi.
This was achieved through integrated partnerships with government entities, the private sector, non-profit third-sector organizations, and particularly voluntary environmental associations, to ensure their sustainability for the current and future generations, he said.
The King Abdulaziz Royal Reserve is one of the seven reserves established by a royal decree. It is a member of the International Union for Conservation of Nature (IUCN) and has an independent authority led by Prince Abdulaziz bin Saud bin Naif bin Abdulaziz.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”